Aduro’s STING pathway technology targets the cytoplasmic Stimulator of Interferon Genes (STING) receptor
STING is known to be a central mediator of innate and adaptive immunity. When stimulated, STING induces the expression of type I interferon, cytokines, and T cell recruitment factors that result in the activation of macrophages and dendritic cells, innate effector cells such as natural killer (NK) cells, and priming of tumor-specific T cells. Natural STING Pathway activators are small molecules generated by bacteria and immune cells.
Aduro has established pioneering expertise in STING Pathway technology and, working in collaboration with academic leaders in the field, has developed synthetic STING Pathway Activators and Inhibitors to treat cancer and autoimmune disorders, respectively.
Aduro’s STING Pathway Activators stimulate tumor-specific immune responses.
Aduro’s synthetic STING Pathway Activators have significantly higher activity than the natural STING ligands produced by bacteria and mammalian cells. These synthetic STING Pathway Activators can be directly injected into tumors, thereby using the tumor itself as a “vaccine,” and enabling the induction of a tumor-specific immune response that is unique to the treated individual - an off-the-shelf small molecule approach to personalized immunotherapy.
STING Pathway Activators are intended to be combined with other cancer therapies and monoclonal antibodies (e.g. checkpoint inhibitors and immune agonists) for a more comprehensive approach to fighting certain cancers. Aduro’s lead molecule, ADU-S100/MIW815, is the first therapeutic in development specifically targeting STING. In collaboration with Novartis, it is being tested in multiple clinical trials in cutaneously accessible tumors, including head-and-neck cancer, melanoma, and multiple other cancers. To date, ADU-S100 has been well-tolerated and is showing encouraging preliminary clinical signals in ongoing early phase trials.
Aduro’s STING Pathway Inhibitors target reduction of autoimmune and inflammatory responses.
Excessive activation of the STING pathway is believed to play a role in the development of an immune response through the induction of proinflammatory cytokines known as type I interferons. Upon inhibition of the STING pathway, the expression of type I interferons is reduced, resulting in a diminution of cytokines and other factors responsible for the activation of the type I interferon-mediated immune response observed in autoimmune disease.
Aduro’s cGAS-STING Pathway Inhibitor program is based on the premise that inhibition of the STING pathway will lead to a reduction in the immune response associated with certain autoimmune diseases. In collaboration with Eli Lilly and Company, Aduro will further its cGAS-STING Pathway Inhibitor program for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases.